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sentative sample of Medicare beneﬁciaries. METHODS: This
study used data from the 2003 Medicare Current Beneﬁciary
Survey (MCBS), a continuous national sample of approximately
12,000 persons. Study patients were 65+ years old, eligible for
Medicare Parts A and B, and community residents. The COPD
cohort comprised patients with 1+ medical claim(s) with a
COPD diagnosis (ICD-9-CM codes: 491.xx, 492.x, 496). The
comparison cohort included non-COPD patients, with at least
one medical claim, matched 1:1 based on age, sex, race, and edu-
cation level. The study measures included self-rated general
health status, self-reported medical conditions, impairment in
activities of daily living (ADLs) and instrumental activities of
daily living (IADLs). RESULTS: A total of 1219 patients were
identiﬁed for the COPD cohort, all of whom were matched to
comparison cohort patients (mean age ± SD: 76 ± 7; 50%
female). COPD patients reported poorer general health (43%
reported “fair” or “poor” health versus 22% among controls; P
< 0.001) and more chronic medical conditions (mean of 4.2
versus 3.2 for controls; P < 0.001). COPD patients were also sig-
niﬁcantly (P < 0.001) more likely to report difﬁculties in per-
forming one or more ADLs (46% versus 28%) or IADLs (42%
versus 26%). For the COPD cohort, the most common ADL lim-
itations were difﬁculty walking (42%) and transferring from a
bed or chair (20%), while the most common IADL limitations
were difﬁculty doing heavy housework (42%) and shopping
(17%). CONCLUSION: In this community-residing Medicare
population, COPD patients reported poorer health and had
greater impairment in functioning than those without COPD.
These results have implications for improving COPD manage-
ment in the Medicare population.
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OBJECTIVES: Economic beneﬁts of early initiation of inhaled
corticosteroids (ICS) treatment in patients diagnosed with
Chronic Obstructive Pulmonary Disease (COPD) were assessed
using a large managed care claims database. METHODS: Early
initiation was deﬁned as beginning ICS within three months of
initiation of regular bronchodilators and was compared with
patients who initiated ICS therapy thereafter. To avoid biases due
to the treatment selection, a propensity-score-matching tech-
nique was used. Exacerbation risks and other resource utiliza-
tion per person-year were compared between the two groups. A
two-part model with multivariate logistic and generalized linear
model (GLM) regression was used to estimate differences in
medical, pharmacy, and total service costs. RESULTS: A total of
7712 matched COPD patients with comparable background
characteristics were identiﬁed. Early initiation of ICS was asso-
ciated with lower exacerbation risks and resource utilization.
Patients who started ICS within three months had more ICS pre-
scriptions (3.7 vs. 2.4 prescriptions per year) and higher phar-
macy costs ($4077 vs. $3868: mean difference +$209, p < 0.05).
However, because of lower medical services use, early initiation
of ICS could save medical costs ($13,837 vs. $14,925: mean dif-
ference −$1.089; p < 0.05) and total costs ($17,994 vs. $18,883:
mean difference −$889; p < 0.05). The same trends were
observed for services directly attributable to COPD conditions.
CONCLUSION: Initiating ICS earlier than the current clinical
guideline recommendation may be beneﬁcial to avoid exacerba-
tions and reduce treatment costs.
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OBJECTIVES: Gastrointestinal Stromal Tumours (GIST) are
rare cancers that generate high expenditures in the Mexican
Health System. The purpose of the study was to model the eco-
nomic and health consequences of second-line treatments (pre-
vious imatinib 400 mg/day failure) in adult patients with GIST
in advanced stages within the Social Security Mexican Institute.
METHODS: A cost–effectiveness analysis was developed using
a Markov modeling approach. The model simulates costs and
effectiveness outcomes in a ﬁve-year period. The model aimed 
to compare sunitinib 50 mg/day, imatinib 800 mg/day and local
best supportive care (BSC) as second-line treatments. Transition
probabilities of the Markov model were obtained according to
clinical trials previously published in the literature. Effectiveness
measures were the number of progression-free-months (PFM)
and life-years gained (LYG). The analysis was conducted from
the health care payer’s perspective (only direct medical costs were
used). Resource use and costs data was obtained from hospital
records at Hospital de Oncología CMN “Siglo XXI” in Mexico
City (n = 12). Both costs and health outcomes were discounted
using a 3% annual rate. Probabilistic sensitivity analysis was per-
formed and acceptability curves were constructed. RESULTS:
Second line treatment with imatinib showed the highest expected
costs (US$37,197.8 ± 1368.8) followed by sunitinib
(US$16,641.0 ± 368.6) and BSC (US$1900.7 ± 404.2). On the
other hand, the best clinical outcomes were obtained by suni-
tinib in both PFM and LYG (5.64 months, 1.4 years) followed
by imatinib (5.28 months, 1.3 years) and BSC (2.52 months, 1.1
years). Imatinib option resulted dominated by sunitinib and the
ICER between sunitinib and BSC was of US$49,134.3 per LYG.
Results were robust to Monte Carlo second order sensitivity
analysis and acceptability curves showed the same results. CON-
CLUSION: In Mexico, sunitinib second-line treatment was the
most cost—effective alternative compared to imatinib. These
results should be taken into account by Mexican decision makers
in the management of patients with GIST.
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OBJECTIVES: Colorectal cancer is the second most commonly
diagnosed cancer and the third cause of cancer-related mortality
in Taiwan. Capecitabine, an oral ﬂuoropyrimidine, is an effec-
tive alternative to intravenous ﬂuorouracil plus leucovorin (5-
FU/LV) in adjuvant treatment of stage III colon cancer. The
